Eight organizations awarded with more than $180,000 in patient-centric funding for the narcolepsy and rare disease communities
PLYMOUTH MEETING, PA, September 22, 2021 — Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced winners of the Patient at the Heart and Progress at the Heart programs in honor of the third annual World Narcolepsy Day.
The Patients at the Heart program was created in 2019, and awards funds to not-for-profit organizations working to support and address the challenges of people living with sleep disorders and rare diseases who experience excessive daytime sleepiness (EDS). Initiated in 2021, Progress at the Heart supports innovative programs that address disparities, injustice, and inequities in the rare disease and sleep disorder community.
"We are so inspired by the diverse and inventive programs submitted for this year’s Patients and Progress at the Heart programs," said Cate McCanless, SVP, Corporate Affairs and Public Policy. "Our goal is to improve the lives of people living with sleep disorders and their families, and we hope by supporting these cutting-edge programs, we can make a positive difference for these communities."
The company chose to announce the winners on World Narcolepsy Day, a day dedicated to raising awareness for this sleep disorder globally. The first Patients at the Heart program awarded $65,000 to four organizations, which was increased to $74,000 in 2020. Now, combined with the Progress at the Heart recipients, total funds awarded in 2021 increased to over $180,000 awarded to eight organizations across the United States.
The following organizations, by category, were chosen as the 2021 Patients at the Heart recipients:
Rare Diseases with EDS
The following organizations and programs were chosen as the 2021 Progress at the Heart recipients:
Community Health Clinic: Enhancing Sleep Health Awareness Among Chicago’s Medically Underserved Population
Duke Department of Neurology: Duke Health Disparities in Neurology Scorecard
Florida Sickle Cell Center: CRiSIS (Circadian Rhythm & Sleep Impact on Sickle Cell)
Project Sleep: Focus Groups to Understand Barriers and Improve Sleep Disorders Awareness, Diagnosis, and Treatment in Black American Communities
The Hypersomnia Foundation (HF): Diversity, Equity, and Inclusion (DEI) Initiative
The Sleep Doctor: Bio-Rhythm Program
About Harmony Biosciences
Harmony Biosciences is a commercial stage pharmaceutical company headquartered in Plymouth Meeting, PA. The Company was established by Paragon Biosciences, LLC, and is focused on providing novel treatment options for people living with rare neurological diseases who have unmet medical needs. For more information on Harmony, please visit the company's website: www.harmonybiosciences.com.
Harmony Biosciences Media Contact:
Harmony Biosciences Investor Contact: